RESUMO
BACKGROUND: Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir. METHODS: This double-blind, prospective, randomized study involved 1956 patients from 19 countries, who were infected with human immunodeficiency virus type 1 and who had not previously received abacavir. We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir treatment (prospective-screening group), or to undergo a standard-of-care approach of abacavir use without prospective HLA-B*5701 screening (control group). All patients who started abacavir were observed for 6 weeks. To immunologically confirm, and enhance the specificity of, the clinical diagnosis of hypersensitivity reaction to abacavir, we performed epicutaneous patch testing with the use of abacavir. RESULTS: The prevalence of HLA-B*5701 was 5.6% (109 of 1956 patients). Of the patients receiving abacavir, 72% were men, 84% were white, and 18% had not previously received antiretroviral therapy. Screening eliminated immunologically confirmed hypersensitivity reaction (0% in the prospective-screening group vs. 2.7% in the control group, P<0.001), with a negative predictive value of 100% and a positive predictive value of 47.9%. Hypersensitivity reaction was clinically diagnosed in 93 patients, with a significantly lower incidence in the prospective-screening group (3.4%) than in the control group (7.8%) (P<0.001). CONCLUSIONS: HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)
Assuntos
Didesoxinucleosídeos/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Testes Genéticos , Antígenos HLA-B/genética , Testes do Emplastro , Inibidores da Transcriptase Reversa/efeitos adversos , Adolescente , Adulto , Idoso , Didesoxinucleosídeos/uso terapêutico , Método Duplo-Cego , Hipersensibilidade a Drogas/genética , Hipersensibilidade a Drogas/prevenção & controle , Feminino , Marcadores Genéticos , Genótipo , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , HIV-1 , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores da Transcriptase Reversa/uso terapêuticoRESUMO
Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45% of individuals who carry HLA-B*57:01 can tolerate ABC. We investigated immune and non-immune related genes in ABC HSS (n = 95) and ABC tolerant (n = 43) HLA-B*57:01 + patients to determine other factors required for the development of ABC HSS. Assignment of phenotype showed that ABC HSS subjects were significantly less likely than tolerants to carry only ERAP1 hypoactive trimming allotypes (p = 0.02). An altered self-peptide repertoire model by which abacavir activates T cells is in keeping with observation that endoplasmic reticulum aminopeptidase 1 (ERAP1) allotypes that favour efficient peptide trimming are more common in ABC HSS patients compared to patients who tolerate ABC. Independently, non-specific immune activation via soluble cluster of differentiation antigen 14 (sCD14) may also influence susceptibility to ABC HSS.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Didesoxinucleosídeos/uso terapêutico , Síndrome de Hipersensibilidade a Medicamentos/genética , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Infecções por HIV/tratamento farmacológico , HIV-1/fisiologia , Antígenos HLA-B/genética , Alérgenos/imunologia , Aminopeptidases/genética , Fármacos Anti-HIV/imunologia , Didesoxinucleosídeos/efeitos adversos , Didesoxinucleosídeos/imunologia , Síndrome de Hipersensibilidade a Medicamentos/etiologia , Feminino , Estudos de Associação Genética , Predisposição Genética para Doença , Genótipo , Infecções por HIV/complicações , Humanos , Receptores de Lipopolissacarídeos/genética , Masculino , Antígenos de Histocompatibilidade Menor/genética , Fenótipo , Estudos RetrospectivosRESUMO
Pharmacogenetics (PGx) - the study of DNA variation in the human genome and the way this impacts the efficacy and safety of medicines - is becoming an increasingly important research tool as physicians, patients, regulatory authorities and payers look for innovative ways to improve the risk:benefit ratio of medicines. While scientific knowledge about PGx is rapidly increasing, implementation of PGx findings to patient care has yet to be fully achieved. One area where significant progress has been made is in the identification of PGx markers associated with variable response to antiretroviral medicines. For example, the major histocompatibility complex HLA-B*5701 allele has been associated with hypersensitivity to abacavir (ABC) by several independent researchers. While PGx associations have been identified largely through retrospective examination, the clinical utility of these PGx markers in patient care has not been prospectively determined in a randomized study. This paper outlines the design of a study to evaluate the utility of prospective screening for HLA-B*5701 to reduce the incidence of ABC hypersensitivity in an ABC-naïve population of HIV-infected subjects. This represents the first fully powered, randomized, blinded, prospective study to determine the clinical utility of PGx screening to reduce drug-associated adverse events in any patient population. This type of trial design may have utility for other important medicines which have treatment-limiting side effects.
Assuntos
Fármacos Anti-HIV/efeitos adversos , Ensaios Clínicos como Assunto/métodos , Didesoxinucleosídeos/efeitos adversos , Hipersensibilidade a Drogas/genética , Infecções por HIV/tratamento farmacológico , Antígenos HLA-B/genética , Interpretação Estatística de Dados , Humanos , Farmacogenética , Estudos Prospectivos , Projetos de Pesquisa , Tamanho da AmostraRESUMO
BACKGROUND: Leukemia inhibitor factor (LIF) is thought to play a substantial role in protecting CD4 T cells in lymphoid tissues (LT) from infection by HIV-1. OBJECTIVE: To investigate whether primary HIV-1 infected subjects with sustained virological control (< 1000 HIV-1 RNA copies/ml plasma) post-cessation antiretroviral therapy (ART) had a higher initial LIF response during primary HIV-1 infection (PHI) as compared with those individuals who did not achieve a similar control (> 9000 HIV-1 RNA copies/ml plasma) of HIV-1 replication. MATERIAL AND METHODS: Consecutively obtained HIV plasma samples were collected from primary HIV-1 infected subjects. A group of acutely Epstein-Barr virus-infected subjects and a group of HIV-1-seronegative healthy individuals served as controls. All samples were tested by ELISA for LIF and sgp130, the soluble form of LIF's signalling receptor. RESULTS: LIF and sgp130 plasma levels were significantly increased in primary HIV-1-infected subjects as compared with HIV-1-seronegative controls. Peak plasma levels of LIF occurred during the first week of PHI whereas sgp130 peaked between 2 and 4 weeks after the onset of PHI. Furthermore a positive correlation was found between viral load and plasma levels of LIF during PHI. Both LIF and sgp130 plasma concentrations were significantly lower during the viral rebound phase after treatment interruption as compared with the PHI phase. CONCLUSIONS: LIF induction occurred in the initial stages of viral dissemination during PHI. It may be a part of the virally induced generalized pro-inflammatory response. LIF levels at PHI did not predict low levels of HIV viraemia after discontinuation of ART. LIF was not increased following ART interruption in this early treated population.
Assuntos
Infecções por HIV/imunologia , HIV-1/imunologia , Interleucina-6/imunologia , Doença Aguda , Adulto , Antirretrovirais/uso terapêutico , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Receptor gp130 de Citocina/sangue , Receptor gp130 de Citocina/imunologia , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Interleucina-6/sangue , Fator Inibidor de Leucemia , Contagem de Linfócitos/métodos , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Carga Viral , Replicação Viral/imunologiaRESUMO
BACKGROUND: The clinical treatment of patients with HIV and adverse drug events may be enhanced by an understanding of the underlying mechanisms. About 4% of patients with HIV receiving the potent antiretroviral drug abacavir develop a hypersensitivity reaction. This idiosyncratic reaction appears to have an immunologic component that has yet to be defined. Given that the T-cell type 2 cytokine IL-4 may be overproduced by patients with allergy or other immunologic dysregulation, an index cytokine profile could help elucidate the character of a drug-specific hypersensitivity reaction. OBJECTIVE: Quantitation of the production of the type 2 IL-4 and the counterregulatory type 1 cytokine IFN-gamma in patients with abacavir-related hypersensitivity. METHODS: Intracellular cytokines were enumerated in blood T cells by flow cytometry. Subjects were grouped for evaluation as patients with a hypersensitive response after abacavir treatment, patients initiating abacavir who also were evaluated again after 1 month on abacavir, patients on abacavir for 6 months without hypersensitivity, and HIV-naive control individuals. RESULTS: There was a significant association between increased IL-4 production by CD4 and CD8 T lymphocytes and hypersensitivity reactions to abacavir. Lymphocytes from hypersensitive subjects expressed CD28 and the anti-HIV chemokine macrophage inflammatory protein 1beta with a frequency comparable with HIV-naive control cells, suggesting the possibility that the activated T cells from patients with hypersensitivity are functional. CONCLUSION: The expansion of type 0 and type 2 T cells phenotyped by IL-4 production may correlate with abacavir-associated hypersensitivity. The data suggest a cytokine bias that may facilitate B-cell differentiation and downregulate T-cell cytotoxic responses.